Abiomed (ABMD) Halted Ahead of FDA Meeting on Blood Pumps
- Wall Street ends higher, driven by energy amid global tension
- UPDATE: HP, Inc. (HPQ) Misses Q4 EPS by 3c; Issues Q1, FY16 EPS Guidance
- Market Wrap: Revised Q3 GDP Shows Growth; E. Coli Breakout Reported at Costco; KaloBios Volatility Continues
- Putin Says Loss of Russian Warplane Due to Backstabbing; Will Have Serious Consequence for Turkey Ties
- After-Hours Stock Movers 11/24: (PBMD) (VEEV) (GES) Higher; (HPQ) (PTCT) Lower (more...)
Abiomed, Inc. (NASDAQ: ABMD) halted ahead of FDA advisory committee meeting over nonroller-type cardiopulmonary bypass blood pumps.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Novartis (NVS) Receives FDA Approval of First Seasonal Flu Vaccine with an Adjuvant
- Aduro Biotech (ADRO) Announces All Clinical Trials Continue Unaltered
- Adaptimmune Therapeutics (ADAP) Initiates T-Cell Therapy Phase 1/2 in NSCLC
Create E-mail Alert Related CategoriesFDA, Trading Halts
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!